Sara Varnado

Sinus tachycardia is associated with impaired exercise tolerance following heart transplantation

Sinus tachycardia often presents in heart transplantation (HTx) recipients, but data on its effect on exercise performance are limited.

Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor

Antiplatelet drugs are the cornerstone of therapy in many cardiovascular conditions. With the current success and increased use of transcatheter aortic valve implantation (TAVI), the use of antiplatelet therapy is considered part of the medical therapy for these patients. Clinicians caring for these patients need to have a thorough understanding of the pharmacology, pharmacokinetics, pharmacodynamic, and clinical efficacy and safety of commonly used antiplatelet therapy. While aspirin therapy is widely used, dual antiplatelet therapy with clopidogrel has become part of standard of care. Despite the extensive experience with clopidogrel, there are limitations such as drug interactions, metabolism genetic polymorphisms, and variability in the antiplatelet response. More predictable and more potent antiplatelet agents, prasugrel and ticagrelor, have demonstrated superior reductions in ischemic endpoints as part of dual antiplatelet therapy compared to clopidogrel, but at the cost of more major bleeding in patients with an acute coronary syndrome. Significant research needs to be conducted in the setting of TAVI to help define the optimal antiplatelet regimen.

Effect of Diltiazem on Exercise Capacity after Heart Transplantation

Sinus tachycardia (ST) is common after heart transplantation (HTx). The aim of the study was to evaluate the effect of diltiazem treatment during the first year after HTx on heart rate (HR), cardiac allograft function, and exercise capacity.

CARDIAC ALLOGRAFT SINUS TACHYCARDIA IS ASSOCIATED WITH IMPAIRED EXERCISE TOLERANCE

Exercise performance, an important aspect of quality of life, remains limited after heart transplantation (HTx). Sinus tachycardia often presents in HTx recipients, but its effect on functional capacity remains unknown. Based on heart rate (HR) 3 months after HTx, 198 patients transplanted from